Zurich · London · Frankfurt
Independent transaction management for private capital.
Breslin supports institutional investors, corporates and founders on private equity and venture secondaries, fund stakes, spin-offs and new companies. Independent and Swiss, led by its partners since 1996.
Judgement you can defend
Partners who understand the asset before they structure the deal.
Breslin advises across life sciences, chemicals, energy, industrials and technology. The partners combine decades of banking and board experience with genuine technical depth, including doctorates in chemistry, biochemistry and immunology.
That range shapes how we advise. A chemicals portfolio, an energy platform, an industrial technology business or a biotech asset cannot be marketed as a commodity. Its value sits in what the company actually does, and the transaction has to be built around it. Breslin acts as adviser and, on its venture desk, as broker. It takes no principal positions. We are a long term strategic partner to our clients.
What we do
Five practices, one standard.
- Venture
Venture primaries and secondaries
Shares in late-stage and pre-IPO AI, compute and high-tech companies, bought in a funding round or from an existing shareholder.
- Secondaries
Portfolio secondaries
Selling holdings in many private companies at once, often across several countries, as one transaction.
- Fund stakes
Fund stakes
Selling or buying LP interests in private equity, venture and growth funds, including continuation funds. Guide: what LP interests fetch in 2026.
- Spin-offs
Spin-offs, partnering and licensing
University and corporate research turned into a company, a licence or a partnership, and funded.
- NewCo
NewCo and headquarters
Swiss, UK or Luxembourg companies for businesses built elsewhere: set up, run and prepared for a first financing.
Sector focus
Where our fluency runs deepest.
Life sciences
Biotech, pharma, medtech, diagnostics and digital health, from platform to portfolio.
Industrials & Chemicals
Industrial biotech, agro and food, and chemistry led businesses with technical depth.
Energy transition
Cleantech and new energy positions held by corporates, banks and funds.
Applied technology
AI and compute, defence, fintech and selected industrial technology.
Insights
Recent analysis.
- Secondaries · GP-Led
Continuation Funds in 2026: ILPA’s New Guidance and the LP’s Sell-or-Roll Decision
What ILPA’s October 2026 guidance changed, and how LPs should decide whether to sell or roll.
→
- Corporate Finance · Spin-offs
Spin-Offs, Part 2: The First Two Years After Separation
Flowback, the two-year tax window, activists and the parent left behind.
→
- Venture · Pre-IPO
From Pre-IPO to Public: Lock-Ups, Transfer Freezes and What SPV Holders Receive
How staged lock-ups, transfer freezes and SPV distributions decide when pre-IPO holders can sell.
→
Partners and clients
Institutions Breslin has advised or worked alongside.

















The Swiss base
Why it matters that Breslin is Swiss.
Breslin has been domiciled in Zurich since 1996. Clients gain from what that implies in practice: discretion and confidentiality as a professional norm, a stable political and financial environment, neutrality in cross border situations, and a regulatory culture built on rigour. Precision is a national habit. We treat it as a professional obligation.
Considering a transaction, a financing or a strategic review?
A first conversation is confidential and carries no obligation. It is answered by a partner.
